CD274 and breast cancer: A growing number of studies have found that patients selected by biomarkers like the expression of programmed death protein 1 ligand (PD-L1) demonstrate increased benefit in immunotherapy, particularly in combination therapies, prompting intensive research on combination therapy and such biomarkers in the context of breast cancer.